Dobutamine stress echocardiography and the effects of trimetazidine on left ventricular dysfunction in patients with coronary artery disease

Trimetazidine, a metabolic agent that is opening the way to a new class of 3-ketoacyl coenzymeA thiolase inhibitors, has been shown to improve exercise tolerance and increase the ischaemic threshold in patients with effort angina, both in monotherapy or in combination with other anti-anginal drugs....

Full description

Saved in:
Bibliographic Details
Published inCoronary artery disease Vol. 12 Suppl 1; p. S19
Main Author Chierchia, S L
Format Journal Article
LanguageEnglish
Published England 01.02.2001
Subjects
Aged
Cardiotonic Agents
Coronary Disease - diagnostic imaging
Coronary Disease - physiopathology
Cross-Over Studies
Dobutamine
Double-Blind Method
Exercise Test
Female
Humans
Male
Middle Aged
Trimetazidine - pharmacology
Ultrasonography
Vasodilator Agents - pharmacology
Ventricular Dysfunction, Left - drug therapy
Ventricular Function, Left - drug effects
Online AccessGet more information

Cover

More Information
Summary:Trimetazidine, a metabolic agent that is opening the way to a new class of 3-ketoacyl coenzymeA thiolase inhibitors, has been shown to improve exercise tolerance and increase the ischaemic threshold in patients with effort angina, both in monotherapy or in combination with other anti-anginal drugs. The aim of this study was to assess the effects of oral trimetazidine on the ischaemic threshold and left ventricular dysfunction of patients with coronary artery disease. Dobutamine stress echocardiography was used, a technique that allows direct visualisation of localised left ventricular dysfunction that occurs as a result of ischaemia. Dobutamine increases heart rate and contractility thus augmenting oxygen demand. In coronary artery disease, this increased demand leads to metabolic changes responsible for decreased wall thickness and abnormal wall motion.
ISSN:0954-6928